Less than a year into a rocky rollout for its gene therapy Roctavian, BioMarin is now talking about whether the product might be a better fit outside the company, and cutting several ...
READ MORENeurocrine Biosciences’ newly-debuted campaign acknowledges the frustration that congenital adrenal hyperplasia (CAH) patients, families and endocrinologists often feel.
READ MORENovartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut.
READ MOREMerck KGaA is allocating over €300 million ($321.8 million) to build a new research building at its headquarters in Darmstadt, Germany to study technologies for its life science business.
READ MORE